BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36143981)

  • 21. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
    Dubaere E; Goffaux M; Wanet M; Bihin B; Gheldof C; Demoulin AS; Bolly A; Bustin F; Duplaquet F; Baugnee PE; Gustin M; Hers V; Maisin F; Marchand E; Ocak S; Pirard L; Vancutsem O; Van Neck E; Vandermoten G; Zaharia L; Remouchamps V
    BMC Cancer; 2019 Jun; 19(1):639. PubMed ID: 31253136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC).
    Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R
    Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study.
    Sahin B; Atalar B; Kaytan Saglam E; Akgun Z; Abacioglu U; Arifoglu A; Ozyar E; Yaprak G; Ozseker Isik N; Guney Y; Caglar HB; Karaman S; Igdem S; Selek U; Berber T; Oner Dincbas F; Sengoz M; Yucel S; Demiral AN; Akyurek S
    Clin Respir J; 2020 Nov; 14(11):1050-1059. PubMed ID: 32749053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
    Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
    Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?
    Mahmood S; Bilal H; Faivre-Finn C; Shah R
    Interact Cardiovasc Thorac Surg; 2013 Nov; 17(5):845-53. PubMed ID: 23900381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
    Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The management of stage I Non-Small cell lung cancer (NSCLC) in Ontario: A Population-Based study of patterns of care and Stereotactic Ablative Body radiotherapy (SABR) utilization from 2010 to 2019.
    Ashworth A; Kong W; Owen T; Hanna TP; Brundage M
    Radiother Oncol; 2024 May; 194():110153. PubMed ID: 38364940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
    Wood A; Aynsley E; Kumar G; Masinghe S; Anderson M; Veeratterapillay J; Huntley C; Blower A; Green J; Johnson D; Daniel J; Curtis H; Reynolds J; Turnbull M; Harland K; Swingler A; Banham E; Burke K; Bradley J; Greenhalgh A; Peedell C
    Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
    Ricardi U; Frezza G; Filippi AR; Badellino S; Levis M; Navarria P; Salvi F; Marcenaro M; Trovò M; Guarneri A; Corvò R; Scorsetti M
    Lung Cancer; 2014 Jun; 84(3):248-53. PubMed ID: 24681279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimally invasive lobectomy versus stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
    de Ruiter JC; van Diessen JNA; Smit EF; van der Noort V; Damhuis RAM; Hartemink KJ;
    Eur J Cardiothorac Surg; 2022 Aug; 62(3):. PubMed ID: 35348664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.
    Soldà F; Lodge M; Ashley S; Whitington A; Goldstraw P; Brada M
    Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes in patients with central and ultracentral non-small cell lung cancer treated with stereotactic body radiotherapy: single-institution experience.
    Song X; Zhao L; Jiang N; Ding N; Zong D; Zhang N; Wang D; Wen J; He X; Kong C; Zhu X
    Curr Probl Cancer; 2023 Jun; 47(3):100956. PubMed ID: 36966677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
    Tekatli H; van 't Hof S; Nossent EJ; Dahele M; Verbakel WFAR; Slotman BJ; Senan S
    J Thorac Oncol; 2017 Jun; 12(6):974-982. PubMed ID: 28286243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer.
    Sumodhee S; Bondiau PY; Poudenx M; Cohen C; Naghavi AO; Padovani B; Maneval D; Gal J; Leysalle A; Ghalloussi H; Otto J; Doyen J
    BMC Cancer; 2019 Apr; 19(1):305. PubMed ID: 30943943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC.
    van den Berg LL; Klinkenberg TJ; Groen HJM; Widder J
    J Thorac Oncol; 2015 May; 10(5):826-831. PubMed ID: 25629639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereotactic Ablative Radiotherapy Using CyberKnife for Stage I Non-small-cell Lung Cancer: A Retrospective Analysis.
    Hayashi K; Suzuki O; Shiomi H; Nakai M; Fujiwara K; Nakanishi E; Tatekawa S; Hirata T; Tamari K; Hirata H; Funaki S; Seo Y; Takeda Y; Isohashi F; Shintani Y; Ogawa K
    Anticancer Res; 2022 Jan; 42(1):321-327. PubMed ID: 34969740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort.
    Murray L; Ramasamy S; Lilley J; Snee M; Clarke K; Musunuru HB; Needham A; Turner R; Sangha V; Flatley M; Franks K
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):4-12. PubMed ID: 26474546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SABR vs. Limited Resection for Non-small Cell Lung Cancer: Are We Closer to an Answer?
    Chen H; Louie AV
    Curr Treat Options Oncol; 2016 Jun; 17(6):27. PubMed ID: 27098533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival analysis after stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a single-institution cohort study.
    Resova K; Knybel L; Parackova T; Rybar M; Cwiertka K; Cvek J
    Radiat Oncol; 2024 Apr; 19(1):50. PubMed ID: 38637844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.